Navigation Links
Nile Therapeutics to Transition to OTCQB Marketplace
Date:5/11/2011

and reporting with the Securities and Exchange Commission. The Company expects its common stock will continue to trade under the "NLTX" symbol on the computerized OTCQB system. Investors will be able to view Level II Real Time stock quotes for Nile at http://www.otcmarkets.com.

About Nile Therapeutics

Nile Therapeutics, Inc. is a biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, cenderitide, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally designed natriuretic peptide. More information on Nile can be found at http://www.nilethera.com.

Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Nile's transition from The Nasdaq Capital Market to the OTCQB Marketplace, including the timing of trading of and the prospects for a market developing for Nile's securities on the OTCQB, are forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Nile makes. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that Nile makes include Nile's need to raise additional capital to fund its product development program
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
2. InVivo Therapeutics and The Miami Project to Cure Paralysis Form Strategic Research Collaboration to Develop Novel Treatments for Spinal Cord Injuries
3. Talecris Biotherapeutics Announces Results of Annual Stockholders Meeting
4. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
5. Cell Therapeutics Retires 7.5% Convertible Senior Notes
6. Talecris Biotherapeutics Announces First Quarter 2011 Results
7. Nektar Therapeutics Reports First Quarter 2011 Financial Results
8. Carmell Therapeutics Completes Series A Financing to Advance the Development of Novel Bioactive Plastics
9. Proteon Therapeutics Initiates Patient Enrollment in Phase 2 Clinical Study of PRT-201 in Hemodialysis Patients
10. Talecris Biotherapeutics to Report First Quarter 2011 Financial Results
11. Precision Therapeutics ChemoFx® Demonstrates Significant Role in Selection of Chemotherapy Doublets in Non Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... The laboratory information management systems market ... number of technological advancements due to factors such as ... to integrate healthcare systems, and increasing government support for ... integration. Key players in the market focus on technological ...
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was invited ... seminar on probiotics in San Diego, CA. , The ... for health care professionals. This year’s pre-conference seminar was held ... health. Dr. Leyer spoke about the emerging topics and science ...
(Date:1/22/2015)... DIEGO , Jan. 22, 2015   Cypher ... and Sequenom, Inc. (NASDAQ: SQNM ), ... development agreement for next generation noninvasive prenatal tests ... genome interpretation technology, called Mantis™, to advance analysis ...
(Date:12/24/2014)... 24, 2014  United Therapeutics Corporation (NASDAQ: UTHR ... MDT ) has submitted a pre-market approval application to ... use of Medtronic,s SynchroMed ® II implantable drug ... with United Therapeutics, Remodulin ® (treprostinil) Injection delivered ...
Breaking Biology Technology:Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... of Dane County's largest health systems, Gov. Jim Doyle ... to help healthcare providers convert to electronic health records. , ,But ... the east clinic of Dean Health Systems in Madison, ... address. In that speech, Doyle is expected to outline key initiatives ...
... that could lead to a local expansion, Cardinal Health ... technologies and services (PTS) segment, including the Middleton-based Gala ... billion in cash. , ,Cardinal Health, a Dublin, Ohio-based provider ... since 2002. The transaction is not expected to immediately impact ...
... in a series of articles on developing start-up companies in the ... - By now you have clarified what your intellectual property ... to form an entity. In this column, we will discuss ... find most useful at this early stage. , ,In today's landscape, ...
Cached Biology Technology:Doyle seeks $30M for e-medical record adoption 2Doyle seeks $30M for e-medical record adoption 3Gala Biotech among companies sold for $3.3 billion 2Early Stage: Step 5 - Forming the entity 2Early Stage: Step 5 - Forming the entity 3Early Stage: Step 5 - Forming the entity 4
(Date:12/17/2014)... Dec. 15, 2014 Research and Markets ( ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 Based on ... Samsung introduces for the first time a fingerprint sensor ...
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a technology ... measures the overall facial feature of a person such ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... This release is available in Spanish . ... and their relation to precipitation is the title of the ... the Basque Country (UPV/EHU). In fact, since systems for the detection ... possibility of estimating the precipitation produced in a storm as a ...
... Mich. --- Lakes, streams and wetlands are not isolated ... colleagues are pioneering a new field of research to ... Patricia Soranno, associate professor of fisheries and wildlife, ... to gauge land use and climate change,s impact on ...
... A person,s ability to battle viruses at the cellular ... prions misfold and cluster native proteins to cause disease, ... marks the first discovery of so-called "good" prion-like proteins ... proteins involved in innate immunity: the way the body ...
Cached Biology News:Lightning is less frequent in winter, but is much more noticeable than in summer 2Lightning is less frequent in winter, but is much more noticeable than in summer 3MSU professor launches new field of water research, nets $2.2 million NSF grant 2'Good' prion-like proteins boost immune response, UT Southwestern scientists report 2
Phosphotyrosine IgG mouse monoclonal antibody: Alkaline Phosphatase conjugate...
Rabbit polyclonal to GPCR G2A ( Abpromise for all tested applications). entrezGeneID: 29933 SwissProtID: Q9UNW8...
... reagent has been developed for use ... reduction of nonspecific background staining due ... describe blocking peroxidase with hydrogen peroxide. ... in combination with additional novel components ...
Rabbit polyclonal to Wilms Tumor Protein ( Abpromise for all tested applications). entrezGeneID: 7490 SwissProtID: P19544...
Biology Products: